944 related articles for article (PubMed ID: 37989744)
1. γδ T cells: origin and fate, subsets, diseases and immunotherapy.
Hu Y; Hu Q; Li Y; Lu L; Xiang Z; Yin Z; Kabelitz D; Wu Y
Signal Transduct Target Ther; 2023 Nov; 8(1):434. PubMed ID: 37989744
[TBL] [Abstract][Full Text] [Related]
2. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
[TBL] [Abstract][Full Text] [Related]
3. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
4. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
Li Y; Li G; Zhang J; Wu X; Chen X
Front Immunol; 2020; 11():619954. PubMed ID: 33664732
[TBL] [Abstract][Full Text] [Related]
5. Human liver infiltrating γδ T cells are composed of clonally expanded circulating and tissue-resident populations.
Hunter S; Willcox CR; Davey MS; Kasatskaya SA; Jeffery HC; Chudakov DM; Oo YH; Willcox BE
J Hepatol; 2018 Sep; 69(3):654-665. PubMed ID: 29758330
[TBL] [Abstract][Full Text] [Related]
6. The capability of heterogeneous γδ T cells in cancer treatment.
Yan W; Dunmall LSC; Lemoine NR; Wang Y; Wang Y; Wang P
Front Immunol; 2023; 14():1285801. PubMed ID: 38077392
[TBL] [Abstract][Full Text] [Related]
7. γδ T cell exhaustion: Opportunities for intervention.
Chen D; Guo Y; Jiang J; Wu P; Zhang T; Wei Q; Huang J; Wu D
J Leukoc Biol; 2022 Dec; 112(6):1669-1676. PubMed ID: 36000310
[TBL] [Abstract][Full Text] [Related]
8. Function of γδ T cells in tumor immunology and their application to cancer therapy.
Park JH; Lee HK
Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic avenues for γδ T cells in cancer.
Costa GP; Mensurado S; Silva-Santos B
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007241
[TBL] [Abstract][Full Text] [Related]
10. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
Front Immunol; 2019; 10():1997. PubMed ID: 31507601
[TBL] [Abstract][Full Text] [Related]
11. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.
Maeurer MJ; Martin D; Walter W; Liu K; Zitvogel L; Halusczcak K; Rabinowich H; Duquesnoy R; Storkus W; Lotze MT
J Exp Med; 1996 Apr; 183(4):1681-96. PubMed ID: 8666926
[TBL] [Abstract][Full Text] [Related]
12. The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.
Liu Y; Zhang C
Cells; 2020 May; 9(5):. PubMed ID: 32413966
[TBL] [Abstract][Full Text] [Related]
13. Tumor resistance mechanisms and their consequences on γδ T cell activation.
Wesch D; Kabelitz D; Oberg HH
Immunol Rev; 2020 Nov; 298(1):84-98. PubMed ID: 33048357
[TBL] [Abstract][Full Text] [Related]
14. Renal Cell Carcinoma-Infiltrating CD3
Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
[TBL] [Abstract][Full Text] [Related]
15. Lineage divergence at the first TCR-dependent checkpoint: preferential γδ and impaired αβ T cell development in nonobese diabetic mice.
Feng N; Vegh P; Rothenberg EV; Yui MA
J Immunol; 2011 Jan; 186(2):826-37. PubMed ID: 21148803
[TBL] [Abstract][Full Text] [Related]
16. Exhausted intratumoral Vδ2
Rancan C; Arias-Badia M; Dogra P; Chen B; Aran D; Yang H; Luong D; Ilano A; Li J; Chang H; Kwek SS; Zhang L; Lanier LL; Meng MV; Farber DL; Fong L
Nat Immunol; 2023 Apr; 24(4):612-624. PubMed ID: 36928415
[TBL] [Abstract][Full Text] [Related]
17. Gamma-delta (γδ) T cells: friend or foe in cancer development?
Zhao Y; Niu C; Cui J
J Transl Med; 2018 Jan; 16(1):3. PubMed ID: 29316940
[TBL] [Abstract][Full Text] [Related]
18. γδ T Cells in Tumor Microenvironment.
Imbert C; Olive D
Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
[TBL] [Abstract][Full Text] [Related]
19. γδ T cells acquire effector fates in the thymus and differentiate into cytokine-producing effectors in a Listeria model of infection independently of CD28 costimulation.
Laird RM; Wolf BJ; Princiotta MF; Hayes SM
PLoS One; 2013; 8(5):e63178. PubMed ID: 23671671
[TBL] [Abstract][Full Text] [Related]
20. Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S; Chevalier MF; Benmerzoug S; Cesson V; Schneider AK; Rodrigues-Dias SC; Dartiguenave F; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002184
[No Abstract] [Full Text] [Related]
[Next] [New Search]
